How does xgeva help prevent bone fractures in cancer patients?

How does Xgeva work to stop fractures?

Xgeva contains denosumab, a monoclonal antibody that targets RANKL, a protein needed for the growth and survival of osteoclasts. These cells break down bone. By binding to RANKL, Xgeva stops their formation and activity, slowing the rate at which bone is resorbed and thereby keeping bone strength up in patients whose cancer has spread to the bones.

What happens if a patient stops taking Xgeva?

Stopping Xgeva can trigger a rebound increase in bone turnover. The stored-up activity of osteoclasts activates quickly after the injection schedule ends, sometimes causing rapid bone loss and a higher fracture risk. Patients who discontinue the drug often receive follow-up care with bisphosphonates or other agents to manage that rebound.

How long does Xgeva take to work?

Xgeva begins reducing bone resorption markers within days of the first 120 mg injection. Clinical studies show measurable drops in uNTX and sCTX levels after one week, and clinical benefit in terms of skeletal-related events avoided begins to appear within a month.